Showing results (51-60 of 115) with videos related to
Sort By:
Pageof 12
The Journal of Urology|November 11, 2005
Long-term salvage radiotherapy outcome after radical prostatectomy and relapse predictorsJoseph P Brooks, Paul S Albert, Richard B Wilder, et al.Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|July 2, 2021
Phase I dose escalation trial of stereotactic radiotherapy prior to robotic prostatectomy in high risk prostate cancerCasey Liveringhouse, Austin Sim, Kosj Yamoah, et al.International Journal of Radiation Oncology, Biology, Physics|August 15, 2009
A prospective study of intrafraction prostate motion in the prone vs. supine positionRichard B Wilder, Lucy Chittenden, Albert V Mesa, et al.International Braz J Urol : Official Journal of the Brazilian Society of Urology|July 23, 2015
Dosimetric coverage of the prostate, normal tissue sparing, and acute toxicity with high-dose-rate brachytherapy for large prostate volumesGeorge Yang, Tobin J Strom, Richard B Wilder, et al.International Urogynecology Journal|October 5, 2023
Somatic and autonomic nerve density of the urethra, periurethral tissue, and anterior vaginal wall: an immunohistochemical study in adult female cadaversErryn E Tappy, Denise M O Ramirez, Abby M Stork, et al.Cancer|September 26, 2001
Hematologic recovery after central lymphatic irradiation for patients with stage I-III follicular lymphomaC S Ha, S L Tucker, A I Blanco, et al.Cancer Journal (Sudbury, Mass.)|March 6, 2004
Molecular response of follicular lymphoma to cyclophosphamide, doxorubicin, vincristine, prednisone C(H)OP or COP-based therapy as measured by polymerase chain reaction evidence of translocation (14;18)(q32;q21)Chul S Ha, Ming-Sheng Lee, Peter McLaughlin, et al.Patient Education and Counseling|October 1, 1994
A comparison of education methods and their impact on behavioral change in patients with hyperlipidemiaA S Dobs, R B Masters, L Rajaram, et al.Cancer|June 20, 2001
Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphomaR B Wilder, M A Rodriguez, C S Ha, et al.Cancer|February 22, 2002
Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by radiotherapy with or without prechemotherapy surgical debulking for patients with bulky, aggressive lymphomaRichard B Wilder, Jorge E Romaguera, Susan L Tucker, et al.Pageof 12